Immunotherapy before surgery for advanced stomach cancer
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This trial tests giving an immunotherapy drug before surgery to see if it can increase immune cells in the tumor and improve outcomes for people with advanced stomach cancer. It may help shrink the tumor and make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with stomach cancer (adenocarcinoma) that has not spread to distant organs.
- You have not had prior treatment for this cancer (like surgery, chemotherapy, or radiation).
- You are generally in good health, with normal heart, lung, liver, and kidney function.
- You are willing to use birth control during the study and for a few weeks after.
- You have not had another cancer in the past 5 years and do not have serious infections or immune system disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs given before surgery for locally advanced stomach or gastroesophageal junction cancer. It aims to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether giving a combination of chemotherapy and an immunotherapy drug before surgery helps shrink stomach cancer tumors and improve outcomes. The treatment is given in the neoadjuvant (before surgery) setting for stomach cancer that is locally advanced but not spread.
This study tests whether giving immunotherapy before surgery can help shrink advanced stomach cancer and improve outcomes. Immunotherapy uses your body's own immune system to fight cancer cells.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a new combination (tislelizumab plus apatinib and chemotherapy) before surgery for certain advanced stomach cancers, compared with the standard chemotherapy plus S1. The goal is to shrink the tumor and improve outcomes before and around surgery.
This trial tests a new immunotherapy drug (benmelstobart) given before and after surgery for stomach or gastroesophageal junction cancer. The goal is to see if adding this drug to standard care helps reduce the chance of the cancer coming back.
Hear when a new Advanced Gastric Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.